Longevity claims

What human evidence and regulatory status actually support.

A change in telomeres in cultured cells or a change in an NAD-related biomarker does not show that an injection can extend a person's life or reverse biological aging.

Source-based editorial review; independent clinical review pending. Read the sources.

Evidence by peptide

• Epithalon: Claims about Epithalon (Epitalon) and longevity reach beyond the research. The 2025 telomere paper was a laboratory study in cultured human cells, including breast-cancer cell lines. It did not test injections in people and cannot show that the treatment extends life, reverses biological aging or is safe for human use. [1,2]
• NAD+: NAD+ is a coenzyme, not a peptide. A 2026 systematic review found no eligible clinical outcome trials of intravenous, intramuscular, or subcutaneous NAD+ itself for anti-aging or wellness. Oral NR/NMN studies often changed biomarkers, but clinical outcomes were heterogeneous and frequently null. [1]

Common Questions

• Does this page recommend a dose or stack?

  No. Trial protocols describe research, and approved-product instructions apply only to the named formulation and labeled population.

• Can animal, cell or mechanistic findings prove a human benefit?

  No. They can justify further research but cannot be rewritten as a demonstrated outcome in people.

Sources and study limits

1. Epitalon peptide induces telomerase activity and telomere elongation in human cell lines Khavinson V, et al. (2025)
2. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks: Epitalon U.S. Food and Drug Administration
3. NAD+ precursor supplementation in human ageing: a systematic review of clinical evidence and future directions Witkowski M, et al. (2026)
4. 503A Categories Update for September 2026 U.S. Food and Drug Administration (2026)

← Browse all peptides

Educational evidence summary. FDA approval, investigational status, and compounding are separate categories. Use the current label and a licensed clinician for patient-specific decisions.

vialprep research · Sources: PubMed, FDA, peer-reviewed trials · How we verify